A multicenter, open-label, phase 2 study of Velcade (bortezomib) for injection in previously treated patients with stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features

Trial Profile

A multicenter, open-label, phase 2 study of Velcade (bortezomib) for injection in previously treated patients with stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Bronchiolo-alveolar adenocarcinoma
  • Focus Therapeutic Use
  • Acronyms PEAK
  • Most Recent Events

    • 16 Feb 2011 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov.
    • 16 Feb 2011 Actual end date (1 Jul 2007) added as reported by ClinicalTrials.gov.
    • 02 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top